<SEC-DOCUMENT>0001776985-22-000002.txt : 20220105
<SEC-HEADER>0001776985-22-000002.hdr.sgml : 20220105
<ACCEPTANCE-DATETIME>20220105073005
ACCESSION NUMBER:		0001776985-22-000002
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20220105
FILED AS OF DATE:		20220105
DATE AS OF CHANGE:		20220105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		22509437

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190847081

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-kzostercollaboration.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3237e7ea17564975b2fb4b0b1f219554_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a&#8209;16 OR 15d&#8209;16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FOR THE MONTH OF JANUARY 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER 001-39081 </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">BioNTech SE<br></font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">An der Goldgrube 12</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D-55131 Mainz</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Germany</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">+49 6131-9084-0<br></font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20&#8209;F or Form 40&#8209;F&#58; Form 20&#8209;F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Form 40&#8209;F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(1)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(7)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">On January 4, 2022, BioNTech SE (the &#8220;Company&#8221;) and Pfizer Inc. today announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime. The press release is attached hereto as Exhibit 99.1.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.560%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">BioNTech SE</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Dr. Sierk Poetting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Dr. Sierk Poetting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;   Chief Operating Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; January 5, 2022 </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT INDEX </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.905%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Exhibit</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Description of Exhibit</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="ex991zostercollaborationan.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:justify"><font><br></font></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991zostercollaborationan.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ieaa5edf9f95940c1b465b23d4fe7a27a_1"></div><div style="min-height:120.83pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.240%"></td><td style="width:0.1%"></td></tr><tr style="height:56pt"><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:240px"></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><img alt="image_1.jpg" src="image_1.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td></tr></table></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:112%">Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Third mRNA vaccine collaboration between the companies aims to accelerate development of an improved vaccine for shingles, a debilitating, disfiguring and painful disease that affects people all over the world </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Product candidates will be based on BioNTech&#8217;s proprietary mRNA technology and on Pfizer&#8217;s antigen technology </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Clinical trials are expected to start in the second half of 2022 </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">BioNTech will receive $225 million upfront, including an upfront cash payment of $75 million and an equity investment of $150 million, and will be eligible to receive future approval and sales milestone payments totaling up to $200 million as well as a share of gross profits arising from future product sales </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Pfizer will receive an upfront payment of $25 million from BioNTech for its proprietary antigen sequences identified by Pfizer</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">NEW YORK, USA and MAINZ, GERMANY, January 5, 2022 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212; Pfizer Inc. (NYSE&#58; PFE) and BioNTech SE (Nasdaq&#58; BNTX) today announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime. The collaboration builds on the companies&#8217; success in developing the first approved and most widely used mRNA vaccine to help prevent COVID-19. This is the third collaboration between Pfizer and BioNTech in the infectious diseases field, following the influenza vaccine collaboration initiated in 2018 and the COVID-19 vaccine collaboration initiated in 2020.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the agreement, the companies will leverage a proprietary antigen technology identified by Pfizer&#8217;s scientists and BioNTech's proprietary mRNA platform technology used in the companies&#8217; COVID-19 vaccine. The parties will share development costs. Clinical trials are planned to start in the second half of 2022. Pfizer will have rights to commercialize the potential vaccine on a global basis, with the exception of Germany, Turkey and certain developing countries where BioNTech will have commercialization rights. The companies will share gross profits from commercialization of any product.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;Pfizer and BioNTech co-developed the world&#8217;s first mRNA vaccine, providing a well-tolerated and effective tool to help address COVID-19 &#8211; the most devastating pandemic in a century &#8211; and demonstrating consistent, agile and high-quality manufacturing on an unprecedented scale,&#8221; said Mikael Dolsten, M.D., Ph.D., Chief Scientific Officer and President, Worldwide Research, Development &#38; Medical, Pfizer. &#8220;With this agreement, we continue on our journey of discovery together, by advancing mRNA technology to tackle another health challenge ripe for scientific innovation, supported by our world-class manufacturing network.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;The collaboration aims to develop a new mRNA-based vaccine against shingles, leveraging the expertise and resources of both companies,&#8221; said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. &#8220;Adults aged 50 years and older as well as vulnerable populations like cancer patients are at an increased risk of shingles. Our goal is to develop an mRNA vaccine with a favorable safety profile and high efficacy, which is at the same time more easily scalable to support global access.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the agreement, Pfizer will pay BioNTech $225 million in upfront payments, including a cash payment of $75 million and an equity investment of $150 million. BioNTech is eligible to receive future regulatory and sales milestone payments of up to $200 million. BioNTech will pay Pfizer $25m for the company&#8217;s proprietary antigen technology. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About Shingles (Herpes Zoster Virus)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Shingles (HZV) is a chronic form of the varicella zoster virus (VZV), which causes an initial chickenpox infection. After chickenpox disease, the virus remains dormant in human nerve cells and can re-activate later in life, due to a trigger such as stress or immunocompromise. This attack can lead to extremely painful, disfiguring patches, which may continue to be painful after the episode has </font></div><div style="height:59.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:120.83pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">resolved, a condition known as postherpetic neuralgia (PHN). In rare conditions, shingles can also lead to facial paralysis, deafness and blindness.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">According to the U.S. Centers for Disease Control and Prevention, studies show that more than 99 percent of Americans 40 years and older have had chickenpox, even if they don&#8217;t remember having the disease. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While there are currently approved vaccines for shingles, there is an opportunity to develop an improved vaccine that potentially shows high efficacy and better tolerability, and is more efficient to produce globally, by utilizing mRNA technology. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About Pfizer&#58; Breakthroughs That Change Patients&#8217; Lives</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and follow us on Twitter at &#64;Pfizer</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and &#64;Pfizer News,</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LinkedIn,</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">YouTube</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and like us on Facebook at Facebook.com&#47;Pfizer.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Pfizer Disclosure Notice </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information contained in this release is as of January 5, 2022. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This release contains forward-looking information about a potential preventative Herpes Zoster Virus (HZV) mRNA vaccine candidate and a strategic research, development and commercialization collaboration between Pfizer and BioNTech for the development of such HZV mRNA vaccine candidate, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and&#47;or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and&#47;or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data&#59; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities&#59; whether regulatory authorities will be satisfied with the design of and results from our clinical studies&#59; whether and when drug applications may be filed in any jurisdictions for a HZV mRNA vaccine candidate&#59; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether a HZV mRNA vaccine candidate will be commercially successful&#59; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and&#47;or other matters that could affect the availability or commercial potential of a HZV mRNA vaccine candidate&#59; whether the collaboration between Pfizer and BioNTech will be successful&#59; the impact of COVID-19 on Pfizer&#8217;s business, operations and financial results&#59; and competitive developments.</font><font style="background-color:#ffff00;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A further description of risks and uncertainties can be found in Pfizer&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221;, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">www.pfizer.com.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About BioNTech</font></div><div style="height:59.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:120.83pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">BioNTech Forward-looking Statements </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This press release contains &#8220;forward-looking statements&#8221; of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, the ability of BioNTech to develop and commercialize a vaccine for the Herpes Zoster Virus (HZV), the ability of BioNTech to achieve the collaboration milestone payments and the timing to commence clinical trials. Any forward-looking statements in this press release are based on BioNTech&#8217;s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these and other risks and uncertainties, see the section entitled &#8220;Risk Factors&#8221; in BioNTech&#8217;s Annual Report on Form 20-F filed with the SEC on March 30, 2021, which is available on the SEC&#8217;s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CONTACTS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Pfizer&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Media Relations </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+1 (212) 733-1226 </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PfizerMediaRelations&#64;pfizer.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Investor Relations </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+1 (212) 733-4848 </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IR&#64;pfizer.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">BioNTech&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Media Relations </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jasmina Alatovic </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+49 (0)6131 9084 1513 </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Media&#64;biontech.de</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Investor Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sylke Maas, Ph.D. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+49 (0)6131 9084 1074 </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Investors&#64;biontech.de</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:59.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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M"&-NC9069CS&A5<="%$(W3^ ^NRY)57H_@DI-XN-]2R_+TWWGQ/&P*3,\ &
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MGSVWI K=/R'D?[)VN!.?JWRB^W>'A]\)>5.R.5U/AVT12DMU/-OMG<?;!1!
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MSR9L%F98;"U$AN;]O_[Q\-B)-R4 ?!G=/P"@*'SF\$N9WUY=.]QIG%0,10$
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M .,B^!D8C^>T/MW_6_SZQP]VR;VG=;42KR=DT/WGA.X? *!/\%<.G0ZR  "
M92_TJ4+W#ZBXN+FVAZA"W+UU3?=?Q]SFLEV1A''WZ DP+H*?_7^W^VV\E![8
M6BA)7'3_0?MVSRZ\]X2-__#8B5<5 NC^<T+W#P#0)_B M=,?5@,  ):]T*<*
MW3^@0O GQV9\OG5-]S\RP:[1W:,GP!BI??9_?GLU7D0/;"V4)%ZZ_^#FXT_5
M\:Q=!==IMA:H_P71_>>$[A\ H$]GOF@0IR,L  #P6?9:GRIT_X"$M<,=>WPJ
MQ.-;USIC.7?=O^#G[[KWO7@I@6(T3BI[4*1-O(@>V%HH21QU_T&W=YYE_1_6
M*UY5)$7WGQ.Z?P" /K5?.?0XYP8  +[$7NM3A>X?2$_PFV-/:7?NXL651_<_
M,K6BT>D'QH%Q"6=@>URD3;AQC)=2GJV%DL17]]__5/__?/J571'7J8YGJ?^E
MT/WGA.X? *!O?GO5CG$2AB\= @"0$WNM3Q6Z?R QY>+?:?-*]S\RG4TWB+L-
M"(R=VN14N&;%BRC/UD))XJ[[#QX>.\W6@ET7UZF.9VEY==#]YX3N'P"@SPYP
MTH8O'0( D!-[K4\5NG\@)>7B?\;G^YU]I0+;776M]OD[IWL@,$9JOPCC[K36
MI_NOY^&QH]/.CC'MV[UX59&"SMY%]U\?W3\ 0-S%S;4=X"3,8F,]7D0  ."9
MO=RG"MT_D(QX\>_TI?\^W7\-8>1IUR)AXN4#RJ-VI5@ZV(H749ZMA9+$:?<_
MT+I:L6OD/=3_"NC^<T+W#P 0]_[Z@QW@),S&T6Z\B   P#-[N4\5NG\@#;4?
M5K?Q^\HUW?_(["HDC-^G3X Q:G?N[-&1,!X/3%L+)8GK[K^?:?T?5BI>3TP7
MW7].Z/X! .)T)HL&J2Y/XT4$  ">V<M]JM#] ]/6O>\M'6S9HU$J:X<[\7+[
MH3.<\]7]JU6,OK8>,#GSVZOV $F5N<WE>/GDV5HH2;QW_T'[=L^NE_=0_Z=%
M]Y\3NG\ @#B=R:)!NO>]>!$! (!G]G*?*G3_P%2%0TZJQ?ELYC:778] =(9S
MOMIKM<_?\0@\,+!VN&,/D(2)ET^>K862)(/NOY]I_1_^- ^/G7A5,15T_SFA
M^P< B'NW^ZT=W:3*_/9JO'P  , Y>\5/%;I_8$K:G3NU_N9+:9Q4\=*[0O<_
MFNKRU*Y"PH1#)EY$H$AJOQ%S<7,=+Z(V6PLE21[=?_]3O5<=S]H5=)UF:X'Z
M/PFZ_YS0_0, Q$EU_TL'6_'R 0  Y^P5/U7H_H&)Z][WOF_^.+>Y;(] P7C\
M+><(W?]H=+;;C,_OB@,3HO9-CK \\2)JL[50DF33_0?=WGF6]7]8KWA5,6%T
M_SFA^P< B).:E_,U7P0  %[#7O%3A>X?F*!VYV[C:%=J=/%RO'_M?T"GP_8U
MEM/9;C-9/(,"C)$]1A)F_ZP9+Y\V6PLE24[=?_]3_=]L+=C5=)WJ>);Z?\KH
M_G-"]P\ $&>'-@GC[HEJ   PE+WBIPK=/S!^W?O>_EE3ZF-BKTP>8P^=#MM7
M]R^UQ_K:=,"D+3;6[6&2*NX.3UL+)4EFW7_P\-C)LOZG YXFNO^<T/T# )2U
M.W=V:),P&;QX P  (O:*GRIT_\!XA+OV<#A]W_Q1JJ%Y4]S5.5]"]S\:J>Z_
MNCR-EP\HV-KACCU,4F7C:#=>/FVV%DJ2_+K__J?Z7Z>['6/:MWOQJF(R=/8?
MNO_ZZ/X! ,JD?DF-7SD$ "!+]J*?*O_N_B]NKL/_44B\G0 Q[<[=T^Y:79Y^
MW_PQY-WNM_/;J_;H\I6UPYUX;=VB^Q^-U&X<+DSQ\@$%TSFMS3C\20Y;"R5)
MEMW_0.MJQ:ZO]U#_3P?=?T[H_C.C,TU$")%-NW,7GSN$O5?J_MT-J0!(>=Y0
M$$*FG)=K"WO13Y6PJ/\E]:XG(63Z66RLY_2U,9V2S%?W;Y<_8>*% \KVGHFJ
M&FPME"09=__!Q6_?V%7VGM;52KR>&#>Z_YS0_6>&:2)"R-#XFO'0F2F:<?@I
M-0!2I$YHA!#-T/T34GHR*_[[2C= OD;"=OE397Y[-5XXH&P7-]?V2$D5=T>H
MK862)._N/VC?[MFU]A[J_TFC^\\)W7]FF"8BA R-KQD/G9FBD,9)%2\? +R:
MU F-$*(9NG]"BDY^Q7]?Z0;(T4A8JEET]U8Q, 7V2$F8>.&TV5HH2;+O_ON9
MUO_-UL+#8R=>58P)W7].Z/XSPS01(61H',UX!!M'NW854N4]OWL+H :=J6]"
MB&SH_@DI-UD6_WVE&R!'(V&I+XKS^3O FM]>M0=+JL0+I\W60DE20O<?='OG
MU?&L77W7H?Z?'+K_G-#]9X9I(D+(T#B:\>B+G=9>_JE@ 'B9SM0W(40V=/^$
M%)I<B_^^T@V0HY&P5/?O:+L!4R-UM^;K\F%KH20II/OO9UK__WSZ55BO>%51
M&]U_3NC^,R-UXT$(T8ROD;O4:2U>. !X"YVI;T*(;.C^"2DQ&1?_?:4;($<C
MX?VSIEW^5*DN3^/E XK'-RI'9FNA)"FG^P_^_.NZV5JP&\%UJN-9ZO^QH_O/
M"=U_9I@F(H0,C:,9C[[2:6UN<SE>. !X"YVI;T*(;.C^"2DN2P=;&1?_?:4;
M($<C89V--N.M5@2F@X-T9+862I*BNO_@X;&39?U_\_&G>%51 ]U_3NC^,\,T
M$2%D:!S-> 1SF\MV%9(DG&#CA0. MY":("*$:(;NGY"R4L(OJ>O< #D:">ML
MM)!VYRY>/J!X4A_GH/L?(:5U__U/]?\O'[ZVF\)[VK=[\:IB5'3_.:'[SPS3
M1(20H7$TXQ'8Y4\5NG\ -4G-XA)"-$/W3T@IF=M<WC]KQC<+.=*Y 7(T$M;9
M:#/\]!WP.>&.S1XLJ>+K:F)KH20IL/L?:%VMV*WA/;_^\4.\GA@)W7].Z/XS
MPS01(61H',UX])6Z?U_;#8 @J5E<0HAFZ/X)*2*+C?6+F^OX3B%3.C= CD9T
M:X<[=OE3)5XX &+=OZ.36Y_N7\#E[]_9#>(]K:N5>#WQ=G3_.:'[SPS31(20
MH?$U*+#+GRJ^MAL 03I3WX00V=#]$Y)_U@YWNO>]^#8A7SHW0(Y&=#H7@L7&
M>KQP #ZQQTNJ.#JY]>G^-;1O]^PV\1[J__KH_G-"]Y\9G=$!(40VC@8%W?N>
M7?Y4<;3= &C2F?HFA,B&[I^0G#.WN5Q=GL8W"+G3N0%R-*+3N1#PTW? E]CC
M)54<G=SZ=/\RVK=[U?&LW3*NTVPM/#QVXE7%J]']YX3N/S,ZHP-"B&P<#0JD
M/J(6%B9>/@!X"YVI;T*(;.C^"<DV2P=;1;WN_T3G!LC12%CG0D#W#WR)/5Y2
MQ=')K4_WKZ3;.Z?^QW-T_SFA^\^,SNB $"(;1X,"NG\ .=&9^B:$R(;NGY ,
M,[^]6O)80N<&R-%(6.="L'2P%2\<@$\6&^OVD$D21R>W/MV_F"SK_Y]/OPKK
M%:\J7H'N/R=T_YG1&1T00F3C:%! ]P\@)SI3WX00V=#]$Y)5YC:7'8V^)D3G
M!LC1WT+G0N!HHP%3IG.<^OH^AZV%DH3N_\G#8Z?96K";R'6JXUGJ_Q'0_>>$
M[C\S.G<=A!#9.!J\2W7_%S?7\?(!P%OH3'T30F1#]T](/MDXVBWS(_\1G1L@
M1R-AWB<&].G<L-']CQ"Z_^=RK?]O/OX4KRI>1/>?$[K_S.C<=1!"9.-H\"[5
M_<<+!P!OI#/U30B1#=T_(3ED[7"GW;F+;P1*I7,#Y&@D;!<^51QM-&#*=&[8
MZ/Y'"-U_Y.&QT[I:L1O*>]JW>_&JXLOH_G-"]Y\9G;L.0HAL' W>Z?X!Y$1G
MZIL0(ANZ?T(<9_"%?UK_B,X-D*.1L%WX5'&TT8 IT[EAH_L?(73_GY5E_?_K
M'S_$ZXDOH/O/"=U_9G3N.@@ALG$T>*?[!Y 3G:EO0HALZ/X)<9G%QOK^69,O
M_'^6S@V0HY&P7?A4<;31@"E;.]RQATR2T/V/$+K_+[G\_3N[N;RG=;42KR<^
MA^X_)W3_F6&:B! R-(X&[SK31#-T_P!JDSJG$4(T0_=/B*?,;Z]N'.WRHO_+
M=&Z '(V$[<*GBJ.-!DR9SLF-[G^$T/V_H'V[9[>8][2N5AX>._&JXN_H_G-"
M]Y\9IHD((4/C:/"N,Y*:H?L'4)O4.8T0HAFZ?T+4,[^]NG2PU3BIJ/Q?2><&
MR-%(V"Y\JE27I_'" ?A$Y^1&]S]"Z/Y?=O/QI^IXUFXWUVFV%JC_7T;WGQ.Z
M_\PP340(&1I',QXZ(ZD9NG\ M4F=TP@AFJ'[)T0NBXWU< FO+D_#\<E7_4>@
M<P/D:"1L%SY5PFX?+QR 3W1.;G3_(X3N?ZAN[YSZOS1T_SFA^\\,TT2$D*%Q
M-..A,Y*:H?L'4)O4.8T0HAFZ?T+DTCBIXDLZWD+G!LC12-@N?*K0_0-?HG-R
MH_L?(73_K]'MG?]\^I7=>JY3'<^&]8I7%9_0_>>$[C\S3!,10H;&T8R'SDAJ
MANX?0&U2YS1"B&;H_@E13#@J0]8.=\*UG+?_WTKG!LC12-@N?*K0_0-?HG-R
MH_L?(73_K_3PV&FV%NP&=!WJ_R^A^\\)W7]FF"8BA R-HQD/G9'4#-T_@-JD
MSFF$$,W0_1/B(XN-]8VCW8N;Z_AJ#T/G!LC12-@N?*K0_0-?HG-RH_L?(73_
MKY=K_=^^W8M7M7AT_SFA^\\,TT2$D*%Q-..A,Y*:H?L'4)O4.8T0HAFZ?T*<
M97Y[=>-HM]VYBR_[^ ^=&R!'(V&[\*E"]P]\B<[)C>Y_A-#]OU7K:L5N1N^A
M_H_0_>>$[C\S3!,10H;&T8R'SDAJANX?0&U2YS1"B&;H_@GQFG#D[I\UXXL_
ME&Z '(V$[<*G2N.DBA<.P"<Z)S>Z_Q%"]S^"+.M_6LGGZ/YS0O>?&::)""%#
MXVC&0V<D-4/W#Z VJ7,:(40S=/^$^,[\]FKCI.K>]^*[@(+IW  Y&@G;A4\5
M1QL-F#*=DQO=_PBA^Q_-KW_\8#>F][2N5N+U+!7=?T[H_C/#-!$A9&@<#=YU
M1E(S=/\ :I,ZIQ%"-$/W3T@.F=M<#E=]G@ 8T+D!<C02M@N?*HXV&C!E.B<W
MNO\10O<_LO;MGMV>WM.Z6GEX[,2K6AZZ_YS0_6>&:2)"R- X&KSKC*1FZ/X!
MU"9U3B.$:(;NGY!\,K>YS*\ ])5N@!R-A.W"IXJCC09,V=+!ECUDDH3N?X30
M_=?QL?//ZGC6;E77:;86J/_I_G-"]Y\9IHD((4/C:/#>.*GL\J=*O'  \$8Z
M4]^$$-G0_1.26^:W5\.!'=\4E$3G!LC12-@N?*HXVFC E.G<L-']CQ"Z_YJZ
MO7/J__S0_>>$[C\S.G<=A!#9.!J\O[_^8)<_5>*% X WTIGZ)H3(ANZ?D#RS
M=+!5[$\ Z-P .1H)VX5/%4<;#9@RG1LVNO\10O=?7[=WWFPMV&WK.M7Q;%BO
M>%6+0?>?$[K_S.C<=1!"9.-H\$[W#R G.E/?A!#9T/T3DFV*_0D G1L@1R/A
MQ<:Z7?XD<;31@"G3N6&C^Q\A=/]C\?#8H?[/"=U_3NC^,Z-SUT$(D8VCP;M4
M]U_XISH!U*<S]4T(D0W=/R&9I\ / .C< #D:">M<"'QUBL T<9R.QM9"24+W
M/RX/CQV=PGA<J8YGV[=[\:H60.=/2?=?']U_9G3N.@@ALG$TXT'W#R G.E/?
MA!#9T/T3DG_F-I>+&EKHW  Y&@GK7 A\=8K -,UOK]I#)DDVCG;CA1-F:Z$D
MH?L?K];5BMW(WE-@_4_WGQ.Z_\SHC X((;)Q-.-!]P\@)SI3WX00V=#]$U)*
M'(W*:M*Y 7*TS74N!'3_P)?8XR55')W<^G3_^<JR_B^MLZ3[SPG=?V9T1@>$
M$-DX&A1(=?_5Y6F\? #P%CI3WX00V=#]$U)0PL%>PO?_=6Z '(V$=2X$\]NK
M\<(!^,0>+ZGBZ.36I_O/6OMVSVYJ[VE=K<3KF2^Z_YS0_6=&9W1 ")&-HT&!
M5/?O:+L!T*0S]4T(D0W=/R%E97Y[]>+F.KYER(O.#9"C$9W4A2!>. #]?O>^
M9P^65'%T<NO3_><NR_K_EP]?/SQVXE7-$=U_3NC^,R,U.B"$:,;1H*#=N;/+
MGRJ.MAL 33I3WX00V=#]$U)<YC:7\Z[_=6Z '(WHE@ZV[/*G2KQP 'A5I09;
M"R4)W?_D='OGU?&LW>:NTVPME%#_T_WGA.X_,TP3$4*&QM>@P"Y_JFP<[<8+
M!P!OH3/U30B1#=T_(85F_ZP9WSCD0N<&R-%(6&>CA>3]; HP&KK_D=E:*$GH
M_B<JU_K_S[\ROR#2_>>$[C\S3!,10H;&UZ# +G^JA!-LO'  \!92L[B$$,W0
M_1-2;G*M_W5N@!R-A'4VVLRG*U.\?$#QPAG;'BRIXNL@M;50DM#]3]J??UTW
M6PMVR[M.=3S;[9W'JYH1NO^<T/UGAFDB0LC0.)KQZ-/] \B(U"PN(40S=/^$
M%)TLZW^=&R!'(V&=C3:3Z6X)U"1UD-+]CQ"Z_REX>.Q0__M"]Y\3NO_,,$U$
M"!D:1S,>?:7N?X8?.@10C]0$$2%$,W3_A)2>_'I6G1L@1R-AG8TVXVJ[ 5.S
M=KAC#Y94H?L?(73_T_'PV/GEP]=V^WM/^W8O7M4LT/WGA.X_,TP3$4*&QM?(
M?;&Q;E<A5>*% X"WD)K%)81HANZ?$/+?U>5I?!/AF<X-D*.1L-1/B:\=[L3+
M!Q1/ZFZ-[G^$T/U/4^MJQ?X)O"?+^I_N/R=T_YF1NO$@A&C&T8Q'7^RT=G%S
M'2\? +R:SM0W(40V=/^$D/^>VUS.:>"A<P/D:"0LU?WSZW> -;^]:@^65(D7
M3INMA9*$[G_*+G[[QOX5O">L5+R>SM']YX3N/S-,$Q%"AL;1C$=?[+3FZUEJ
M &ITIKX)(;+1ZO[CT]@K=.][81T(295PK=TXV@T'T=SFLMVE'24L?SB:X@/,
M)YT;($<CX?=*W?_\]FJ\?$#Q[)&2,/'":;.U4)+0_4]?^W;/_B&\IW6U$J^G
M9W3_.:'[!P H6SK8LN.:5'$T601 D,[4=^.DLG4)(27''B:I\MY[]P_H:'?N
MJLO3C:-=J5\1>WW"8L>KY)/.#9"CX5S8>^WR)TR\?$#9+FZN[6&2,/'R:;.U
M4)+0_2>19?W_RX>O'QX[\:KZ1/>?$[I_ ( RG9FBD(VCW7CY .#5=$YH[_F*
M"?!W]C!)%;I_8"+:G;O&2>7N(8 \AA\Z-T".NO^^TI5IAGM'X.^DGAMU]Z"8
MK862A.X_E6[OO#J>M7\1UVFV%O*H_^G^<T+W#P!0IC-3-,,/'0*H1^>$QOPM
M$+&'2:K0_0.3=7%SO7:X8_=VV527I_$Z>*-S T3W/W+VSYKQ\@$%TSFMS3B<
MJ+*U4)+0_2>4:_W_YU_7\:IZ0_>?$[I_ ("RQDEEAS:I,K>Y'"\? +R:SAP1
MW3\0L8=)JM#] ]/0O>^%JW*XN;>[O5K"0H:EC5? %9T;(%_=__SVJEV%5/&U
MZ8!)DWJ&C.Y_M-#]I_7PV&FV%NS?Q76JX]EN[SQ>55?H_G-"]P\ 4";U*;40
M[S-O !+2F?JF^P<B]C!)%;I_8'K:G;NE@RV[YZLE+&2\Z*[HW #Y*K!UK@4S
M#LM%8**D?D'&UYFM3_>/_Z#^%T3WGQ.Z?P" ,K7NG\(,P,ATIKXYE0$1>YBD
M"MT_,&W5Y:G^!P!<7[EU;H!\-60ZUX(9OH '_)T]1A+&UYFM3_>/9QX>.ZVK
M%?O7\9[V[5Z\JD[0_>>$[A\ H*S=N;-#FX1Q-ZH"H$-GZMMU@P!,@CU,4H7N
M'TB@>]_3.>X^F_GMU7BA_="Y ?(UEM/9;H.$D7F\B$"1U-Y0V3]KQHNHS=9"
M24+WKX/Z7P?=?T[H_@$ XNS0)F&\?W$30$(Z4[AT_T#$'B:I0O</)"/U^\TV
M[MJ=)SHW0'3_=5)=GL:+"!2I<5+9 R1AW WM;"V4)'3_4BY__\[^C;SGXK=O
MXO641_>?$[I_ ( XJ6]PNG[E!D!:.E.X[B:(@$FSATFJT/T#*>V?->V!()(P
M*.K>]^(E]D#G!LA7]U]=GMI52)B-H]UX$8$BJ3TH=G%S'2^B-EL+)0G=OYKV
M[9[],WE/ZVHE7D]M=/\YH?L' (C3F0 ?A(\= AB-SM0WW3\0L8=)JM#] XDI
MU_^-DRI>7 ]T;H!\=?]JWQ4/UZ9X$8$BS6^OV@,D8>+EDV=KH22A^Q?4OMVK
MCF?M'\MU?OGP]<-C)UY5573_.:'[!P"(TYD 'X2/'0(8C<[4-]T_$+&'2:K0
M_0/I;1SMVL-!(4X_0:9S ^2K^V]W[NPJI$V\B$!YNO<]>V@DS-SF<KR(\FPM
ME"1T_YJZO?/\ZO]F:\%+_4_WGQ.Z?P" .)W)HD'XV"& T>B<S>C^@8@]3%*%
M[A^0L'2P98\(A>R?->-EE:=S ^2K^^\K79P&X0X24/LQ#H\?Y+"U4)+0_<OJ
M]LY_/OW*_LE<I]E:".L5KZH>NO^<T/T# ,3I3!8-LMA8CQ<1 %Y!YVS&S"T0
ML8=)JM#] Q*Z]SVUKSH/XK'FT;D!<M?]AY&G78N$X2EX0.W#,$L'6_$BRK.U
M4)+0_2M[>.PT6POVK^8ZU?&L?OU/]Y\3NG\ @#BU'SH,Z=[WXJ4$@&%TIK[I
M_H&(/4Q2A>X?4"$X"!FDW;F+EU6;S@V0N^Y?YW(P"$_! VJ/A;D[K?7I_O$Z
MN=;_XI4VW7].Z/X! .(N;J[M "=M/'YK$T!R.E/?=/] Q!XFJ4+W#PA1>[]S
MD,9)%2^H-IT;('<EF> >R%/P*%F[<V</BK3Q.#EE:Z$DH?MWH76U8O]VWM.^
MW8O74P;=?T[H_@$ ^NP )VW6#G?B102 872FONG^@8@]3%*%[A\0TKWOS6TN
MVT,C;=R]>ZUS ^2N^]?9=$_Q6#0"X](XJ>Q!D38>QW6V%DH2NG\OJ/^GB>X_
M)W3_  !]:I]5F]M<CA<1 (;1F;_U.$<$3)0]3%*%[A_0LG_6M(=&\OAZ]UKG
M!LA=]R_XPQ,>?UP<&)>P_]N#(FU\70X&;"V4)'3_COSZQP_V+^@]K:N5>#T%
MT/WGA.X? *!/9P[\*1<WU_%2 L"+=*:^Z?Z!B#U,4H7N'Y"C]AAR2'5Y&B^E
M,)T;('?=O^ 'QGD*'L7JWO?L$9$\\5)Z8&NA)*'[]Z5]NV?_B-XC6/_3_>>$
M[A\ H$_PAP[#(L5+"0 OTIGZIOL'(O8P216Z?T".X$>>?0U%=&Z W'7_?:7K
MTU-\/7H"C(O@9V#"'6.\E![86BA)Z/[=N?GX4W4\:_^4KA/VPX?'3KRJZ=#]
MYX3N'P"@3W#";7Y[-5Y* 'B1SM0WW3\0L8=)JM#] W*Z][VYS65[@"2,K[Y'
MYP;(8_>O<T5XRMKA3KR40 $$/_CO]&"TM5"2T/U[U.V=YU?_-UL+.O4_W7].
MZ/X! /H$?^APAL_^ W@CG:EONG\@8@^35*'[!Q2M'>[8 R1A?'UW7><&R&/W
MK[;OS7C;_8"QT/S@O\=S6I_N'_5T>^<_GWYE_Z"NTVPMA/6*5S4%NO^<T/T#
M /1ICK-\?6L30'(Z4]]T_T#$'B:I0O</*!)\$CE>1&$Z-T >>S*=K?<\^V?-
M>$&!K E^\'_&[:#.UD))0O?OU\-CI]E:L']3UZF.9Q7J?[K_G-#] P!<4/O0
MY@R?_0?P1CJ3MTZGB8#)L8=)JM#] Z+"K;\]1A+&T;5<YP;(8_<O^-Q)R-+!
M5KR@0-9T[LV>IWO?BQ?4 UL+)0G=OVL/CQV=EGI<J8YGDQ?>.ELU^:;( -T_
M , %S:%6=7D:+R@ ?('.U+>CO@"8#GN8I K=/R!*[=/KCJ[E.C= 'KM_S2_@
MA;0[=_&R ID*>[L]!)+'[Z]OV%HH2>C^,]"Z6K%_6>]IW^[%ZSE%=/\YH?L'
M +B@,V7T/&N'._&" L 7Z)S''/4%P'38PR15Z/X!4=7EJ3U&$L;1,\@Z-T >
MN_^^Y!?P9MQN3& $.B>QYPFWB_&".F%KH22A^\\#]?]XT?WGA.X? .""VFS;
M4YQ^90W ].G,&M'] Q%[F*0*W3\@2NWU:T?-J\X-D*.-]IS.1>%Y^ $\E$/M
M-U\&<7I"Z]/]8]S:MWOV[^L]K:N5>#VG@NX_)W3_   7-+^R%M(XJ>)E!8#/
MT9GZIOL'(O8P216Z?T#78F/='B:IXJCUT;D!<K31GM/9@%'VSYKQL@+9"?NY
MW?D5XNCK+Q%;"R4)W7].J/_'A>X_)W3_   O-#]VR L/ %Y)9^:6[A^(V,,D
M5>C^ 5UKASOV,$D51S6VS@V0HXWV7+@PV'51B-]/C@.OIW-7%L7O)RAM+90D
M=/^9^=CY9W4\:__0KA/VTH?'3KRJDT3WGQ.Z?P" %[)C+EYX / :.E/?=/]
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MZ?ZAI]L[SZ_^;[86'AX[\:H.0_>?$[I_ (!37A[.#MD_:\9+#Z \.E/?=/]
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M P!<VSC:M8,C\5#_ V72F?JF^P<B]C!)%;I_0)?4P,-1C:US ^1HH[V&KQ_
M&V1N<SFS-YCAB,?B?R:[$U>?[A]^M&_W[)[C/:VKE7@]GZ'[SPG=/P# -8\O
M/,Q0_P-%TIGZIOL'(O8P216Z?T"7SK$YXZH-TKD!<K317J.Z/+7KZ"+[9\UX
M98 )<UK\A[0[=_'*.&=KH22A^\=KW'S\J3J>M?N/Z[2N5AX>._&J?D+WGQ.Z
M?P" =U*S<*\/]3]0&IVI;[I_(&(/DU2A^P=TV6,D81S5V#HW0(XVVBO-;Z_:
MU701ZG],D]0OMKPI:X<[\<KX9VNA)*'[QRMU>^?YU?_-UL)GZW^Z_YS0_0,
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M'@D/PC< "A3^XAM'N\JGY?H):U?(;SW:6BA)Z/XQ":VK%;NSD1%"]U\?W3\
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M2$6R?ZB'FS]_D5/ N&3_^9#]!X,V$2+V2L?##B=78Y[;B)DZBK'MM+X=#1I
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M.ZUO1X,&4 8Y3;3\+_N_N;];OF41\0?D\U-3++-2=;DQ0 L[LZ!U_KCH_HD
MI?@R^\V"\\5U]R\#@)>7I^>9G"_E37]&]R^#[\3(I4S^_<]=]X^#[X<V$2+V
M2L<#%)$W)&*FCCI7=II^C@8-H QRFFB9IN>_0L%"C+00/OD     245.1*Y"
"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
MB5!.1PT*&@H    -24A$4@   0\   !O" (   !]SM*'   87$E$051X7NV=
M>7@41?K'DQ NN41D72]<5W%9,EF3:(("*BC&A?@L^ AXH OZ0\1;1%!0\5Q8
M%[D2 @^G@L#B 7*XB(1,((D0C@2$)!"2D/L..<DQ1W?_:M+0TU/5_79/3\\%
M]7F^?_"0JNZ>F?IV76]5!7!Z$+2,Z;R4Z1;']%K!](VWC-[.+C_)Y=3AR2@4
MOR8 _P_GR:OG I9"0EZZ=J5UX'IFW$YV7R%GLN)7H%#\ AW<\ED:;@\UZAEG
MO?\[9DXJ6]J,7Y!"\4UT<$N_> MI!F?5?3DS=A>[(9N]:,:O3Z'X"*ZZA67Q
M<N^Z4,OM@1^8M:?9)A-^.PK%B[CJEJ02O*SKKO$_LVD5-EM2*-[%5;<\^PM+
MEF\WJ7><=6<>;:I1O(:K;@E>9B6+M;L5N-BZ+I.S,/C#4"ANQ56WD$79D^H9
MQVS-P1^)0G$3+KEE7:;GFF&P!FU@LB[@CT>AZ(M+;KEO*T,67"^J\U)FREZ6
MH>,!%/?@DEM0_X$LLKZ@>[?0JH:B/]K=TFK!RZBOJ5<\\^,Y6M%0=$.[6UXW
M^DJG!5;04NLW6?C#4R@:T.Z66U;[:#-,4H&+F0W9^$>@4)Q"NUO($ND7VE.
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MIYN_7U5Z*,%A&5+ \#]"5;F</GTEF]$6'";/EGC9;\&3>GDTWF90R6MC56U
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M\/RPM@P.E/(U-=1I7)/M7>#1:LV;F%"<PE6W\!S<4^/*OF2>%/[H?L+VKZ&
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F>RC:H&[Q1<*[)0+"4U,\Q?\#T6RQDU(D9Z@     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
